SecBot SecBot

ADRX

ADARx Pharmaceuticals, Inc.
Nasdaq· CIK 0001802369 Biotech & Drug Discovery
$17.63 −0.05 (−0.28%)
Oct 23 4:00 PM ET · prev $17.68
Market cap
$1.9B
Small cap
Median target
🔒 Subscribers only
Since first trade
−8.9%
from $19.35 · Sep 25
30 days
−8.9%
from $19.35
Range since listing
$17.13–20.64
−15% from high · low Oct 21
Avg volume 20D
624.0K
shares / day
Short interest
1.16M
≈1.1% of shares
Days to cover
1.7
at average volume
Insider net
+$39.4M
3 buyers · 0 sellers · since Sep 28
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 17 reports · 90 days
Balance 0 bearish · 7 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 17/17
Strongest BULLISH The SEC declared effective ADARx Pharmaceuticals' S-1 registration statement for its initial public offering…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $39.4M at an average $17.00. No open-market sales.

The Street

last action Oct 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 20, 2026TD Cowen
INITIATE
INITIATEBuy
Oct 20, 2026JP Morgan
INITIATE
INITIATEOverweight
Oct 20, 2026UBS
INITIATE
INITIATEBuy
Oct 20, 2026Morgan Stanley
INITIATE
INITIATEOverweight
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 1, 2026
Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public…
Sep 25, 2026
Listing
New Listing: ADRX — ADARx Pharmaceuticals, Inc. - Common stock
Listed on exchange Q
Sep 24, 2026
Offering
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

Insider ledger

Form 4
$39.4M
bought · 3 insiders
$0
sold · 0 insiders
+3.7%
vs their $17.00 cost
DateInsiderTypeValue
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT8,908,775 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT1,667,469 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT513,067 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT153,868 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT307,738 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT10,438,412 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT1,953,774 sh
Sep 28, 2026
LAV Biosciences Fund V, L.P.
10%+ Owner
CONVERT601,161 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,163,375
shares short
1.7
days to cover
≈1.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
LAV Biosciences Fund V, L.P. and affiliated entities (LAV Fund VI, L.P., LAV Fund VI Opportunities, L.P., and Yi Shi)…
SC 13G — Impact 3/10
Oct 5, 2026 SEC
SR One Capital Management, led by Simeon George, filed a Schedule 13D disclosing beneficial ownership of 9,936,661…
SC 13D — Impact 5/10
Oct 2, 2026 SEC
OrbiMed Advisors LLC and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 14,913,764 shares…
SC 13D — Impact 5/10
Oct 1, 2026 Press
ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500…
Impact 7/10
Oct 1, 2026 Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Add
Sep 28, 2026 Insider
LAV Biosciences Fund V, L.P. acquired 8,908,775 shares
10%+ Owner
Sep 28, 2026 Insider
LAV Biosciences Fund V, L.P. acquired 1,667,469 shares
10%+ Owner
Sep 28, 2026 Insider
LAV Biosciences Fund V, L.P. acquired 513,067 shares
10%+ Owner

SecBot reports

15 filings · 2 press releases · 5 bullish · 0 bearish · 10 neutral
All ADRX filing & press-release reports (17)